Search
Now showing items 481-490 of 562
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
(SPRINGER, 2018-02-01)
PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) ...
Characterization of the diffusion coefficient of blood.
(WILEY, 2018-05-01)
PURPOSE: To characterize the diffusion coefficient of human blood for accurate results in intravoxel incoherent motion imaging. METHODS: Diffusion-weighted MRI of blood samples from 10 healthy volunteers was acquired with ...
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
(ELSEVIER SCIENCE BV, 2018-03-01)
BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone ...
Post-Traumatic Growth and Resilience in Adolescent and Young Adult Cancer Patients: An Overview.
(MARY ANN LIEBERT, INC, 2018-02-01)
The aim of this study was to provide an overview of the literature on post-traumatic growth (PTG) and resilience among adolescent and young adult (AYA) cancer patients. A literature search in Embase, PsychInfo, PubMed, Web ...
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2018-01-01)
Background: Ovarian suppression in premenopausal women is known to reduce breast cancer risk. This study aimed to assess uptake and compliance with ovarian suppression using the luteinizing hormone releasing hormone (LHRH) ...
Randomised Controlled Trials Remain the Key to Progress in Localised Prostate Cancer.
(ELSEVIER SCIENCE BV, 2018-01-01)
DESNT: A Poor Prognosis Category of Human Prostate Cancer.
(ELSEVIER, 2018-12-01)
BACKGROUND: A critical problem in the clinical management of prostate cancer is that it is highly heterogeneous. Accurate prediction of individual cancer behaviour is therefore not achievable at the time of diagnosis leading ...
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
(ELSEVIER, 2018-03-01)
BACKGROUND: Evaluation of responses to treatment for metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-specific antigen (PSA) and clinical and radiologic ...
Warthin Tumor-Like Mucoepidermoid Carcinoma.
(SAGE PUBLICATIONS INC, 2018-02-01)
Mucoepidermoid carcinoma (MEC) shows a wide morphologic spectrum, including epithelium with oncocytic or squamous metaplastic changes overlying a prominent cystic architecture, as well as tumor-associated lymphoid tissue. ...
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
(ELSEVIER SCIENCE BV, 2018-01-06)
UNLABELLED: Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies ...